Chemoinformaics analysis of 2-BENZYL-1,3-DIHYDROXYANTHRACENE-9,10-DIONE
| Molecular Weight | 330.339 | nRot | 2 |
| Heavy Atom Molecular Weight | 316.227 | nRig | 25 |
| Exact Molecular Weight | 330.089 | nRing | 4 |
| Solubility: LogS | -4.175 | nHRing | 0 |
| Solubility: LogP | 3.914 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 3 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 39 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 25 | No. of Aromatic Carbocycles | 3 |
| nHetero | 4 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 14 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 21 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 18 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 18 |
| nHA | 4 | APOL | 47.6131 |
| nHD | 2 | BPOL | 15.7809 |
| QED | 0.406 |
| Synth | 2.517 |
| Natural Product Likeliness | 0.604 |
| NR-PPAR-gamma | 0.974 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.065 |
| Pgp-sub | 0 |
| HIA | 0.008 |
| CACO-2 | -5.154 |
| MDCK | 0.0000162 |
| BBB | 0.105 |
| PPB | 1.00651 |
| VDSS | 0.354 |
| FU | 0.00591014 |
| CYP1A2-inh | 0.958 |
| CYP1A2-sub | 0.128 |
| CYP2c19-inh | 0.623 |
| CYP2c19-sub | 0.095 |
| CYP2c9-inh | 0.788 |
| CYP2c9-sub | 0.631 |
| CYP2d6-inh | 0.501 |
| CYP2d6-sub | 0.239 |
| CYP3a4-inh | 0.323 |
| CYP3a4-sub | 0.132 |
| CL | 2.793 |
| T12 | 0.375 |
| hERG | 0.029 |
| Ames | 0.778 |
| ROA | 0.481 |
| SkinSen | 0.607 |
| Carcinogencity | 0.783 |
| EI | 0.254 |
| Respiratory | 0.675 |
| NR-Aromatase | 0.662 |
| Antiviral | Yes |
| Prediction | 0.663119 |